Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GLUE Monte Rosa Therapeutics

Post-Mkt 05-22 17:37:25 EDT

18.81

-0.07

-0.37%

盘后18.81

+0.000.00%

17:36 EDT

High19.79	Low18.45	Vol906.67K
Open18.72	D1 Closing18.88	Amplitude7.12%
Mkt Cap1.59B	Tradable Cap1.16B	Total Shares84.38M
T/O17.31M	T/O Rate1.47%	Tradable Shares61.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GLUE","market":"US","secType":"STK","nameCN":"Monte Rosa Therapeutics","latestPrice":18.81,"timestamp":1779480000000,"preClose":18.88,"halted":0,"volume":906671,"hourTrading":{"tag":"盘后","latestPrice":18.81,"preClose":18.81,"latestTime":"17:36 EDT","volume":40507,"amount":761936.6699999999,"timestamp":1779485789502,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.003707627118644083,"floatShares":61574700,"shares":84382573,"eps":-1.495445,"marketStatus":"Post-Mkt","change":-0.07,"latestTime":"05-22 17:37:25 EDT","open":18.72,"high":19.79,"low":18.445,"amount":17307660.32004,"amplitude":0.071239,"askPrice":20,"askSize":9,"bidPrice":15.55,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.495445,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1779494400000},"marketStatusCode":4,"adr":0,"listingDate":1624507200000,"exchange":"NASDAQ","adjPreClose":18.88,"preHourTrading":{"tag":"盘前","latestPrice":19.99,"preClose":18.88,"latestTime":"09:29 EDT","volume":11406,"amount":215448.27618000002,"timestamp":1779456590557,"change":1.11,"changeRate":0.058792,"amplitude":0.211335},"postHourTrading":{"tag":"盘后","latestPrice":18.81,"preClose":18.81,"latestTime":"17:36 EDT","volume":40507,"amount":761936.6699999999,"timestamp":1779485789502,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.168727,"impliedVol":0.5321,"impliedVolPercentile":0.0598},"requestUrl":"/m/hq/s/GLUE/tweets","defaultTab":"tweets","newsList":[{"id":"2637707341","title":"Monte Rosa director Anthony Manning disposes 10,000 shares worth $180,100","url":"https://stock-news.laohu8.com/highlight/detail?id=2637707341","media":"Reuters","labels":["shareholding","insiderTrades"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2637707341?lang=en_us&edition=fundamental","pubTime":"2026-05-23 04:06","pubTimestamp":1779480381,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics director Anthony M. Manning sold 10,000 common shares on May 21, 2026 at USD 18.01, cutting his direct stake to zero.The sale followed the exercise of a stock option for 10,000 shares at USD 4.16 on the same day.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL3839P3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Monte Rosa director Anthony Manning disposes 10,000 shares worth $180,100","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636849692","title":"Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2636849692","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636849692?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:00","pubTimestamp":1779274800,"startTime":"0","endTime":"0","summary":"BOSTON, May  20, 2026  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/20/3298320/0/en/Monte-Rosa-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634234822","title":"Monte Rosa Therapeutics Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2634234822","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634234822?lang=en_us&edition=fundamental","pubTime":"2026-05-12 03:20","pubTimestamp":1778527200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GLUE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 11, 2026 15:20 ET (19:20 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633173180","title":"Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX) and Monte Rosa Therapeutics (GLUE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633173180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633173180?lang=en_us&edition=fundamental","pubTime":"2026-05-08 03:20","pubTimestamp":1778181622,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Foghorn Therapeutics (FHTX) and Monte Rosa Therapeut...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-foghorn-therapeutics-fhtx-and-monte-rosa-therapeutics-glue-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-foghorn-therapeutics-fhtx-and-monte-rosa-therapeutics-glue-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4137","BK4588","BK4585","FHTX","HCSG","BK4581","BK4139","BK4539","LU0029874061.USD","LU0128526141.USD","GLUE","LABU","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633124245","title":"Monte Rosa Therapeutics reports Q1 revenue $4.21M, consensus $11.39M","url":"https://stock-news.laohu8.com/highlight/detail?id=2633124245","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633124245?lang=en_us&edition=fundamental","pubTime":"2026-05-08 00:19","pubTimestamp":1778170794,"startTime":"0","endTime":"0","summary":"“We continue to make excellent progress advancing multiple programs through the clinic, with all three of our clinical-stage programs approaching P...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-reports-q1-revenue-4-21m-consensus-11-39m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-reports-q1-revenue-4-21m-consensus-11-39m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633128538","title":"Monte Rosa Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633128538","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633128538?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:23","pubTimestamp":1778160202,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryMonte Rosa Therapeutics Inc GLUE.OQ reported a quarterly adjusted loss of 45 cents per share for the quarte","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL8N41K1OS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633146212","title":"Monte Rosa Therapeutics Q1 collaboration revenue drops 95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633146212","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633146212?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:28","pubTimestamp":1778153332,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Q1 collaboration revenue drops 95%OverviewUS biotech firm's Q1 collaboration revenue fell 95% yr/yrCompany posted Q1 net loss after prior-year profitCash position rose after $3","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL1N41K0LO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","GLUE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633462331","title":"Monte Rosa publishes investor presentation on molecular glue degrader pipeline and Phase 2 plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2633462331","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633462331?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:25","pubTimestamp":1778153159,"startTime":"0","endTime":"0","summary":"Monte Rosa outlined plans to start Phase 2 trials in 2026 for three molecular glue degrader programs, including VAV1 degrader MRT-6160, NEK7 degrader MRT-8102, and GSPT1 degrader MRT-2359.Pipeline update flagged Phase 2 initiation for MRT-8102 in Q3 2026, with Phase 1 data for MRT-2359 followed by Phase 2 initiation in H2 2026.Additional wholly owned IND submissions targeted for H2 2026, including CCNE1 MGD, with further INDs anticipated over next two years.Collaboration economics highlighted USD 350 million received in collaboration payments over last three years, with potential for more than USD 400 million over next 24 months.Balance sheet commentary pointed to cash runway into 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL7sXQ0g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145975","title":"Monte Rosa Q1 FY26 net loss widens to $44.5 million; revenue falls to $4.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145975","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145975?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:03","pubTimestamp":1778151805,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics posted a net loss of $44.5 million for first-quarter 2026, swinging from net income of $46.9 million a year earlier, as revenue fell to $4.2 million from $84.9 million.R&D expenses climbed to $44.1 million from $32.2 million, while G&A costs rose to $10.2 million from $8.7 million.Cash, cash equivalents, restricted cash, and marketable securities totaled $671 million at March 31, up from $382.1 million at Dec. 31, following a $345 million public offering in January.Phase 2 starts planned for MRT-8102 in H2 2026, while MODeFIRe-1 Phase 2 for MRT-2359 with apalutamide in mCRPC with AR mutations is slated for Q3 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDLjvK1p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014039.USD","BK4588","LU2095319765.USD","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4139","LU0314104364.USD","GLUE","BK4539","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","IE00BN0W2W23.USD","BK4585","IE00B3QW5Z07.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","SG9999014021.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432301","title":"BRIEF-Monte Rosa Therapeutics Q1 Net Income USD -44.503 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432301","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633432301?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151649,"startTime":"0","endTime":"0","summary":"BRIEF-Monte Rosa Therapeutics Q1 Net Income USD -44.503 Million\n\n\nMay 07 (Reuters) - Monte Rosa Therapeutics Q1 operating income USD -50.034 million.\n\nQ1 collaboration revenue USD 4.21 million\nQ1 operating expenses USD 54.244 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX1A261F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633143976","title":"Monte Rosa Therapeutics Q1 Operating Expenses USD 54.244 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633143976","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633143976?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX1A261F:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLUE","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633143165","title":"Monte Rosa Therapeutics Q1 Operating Income USD -50.034 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633143165","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633143165?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151604,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX1A261F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","GLUE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633314309","title":"Press Release: Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633314309","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633314309?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with elevated CVD risk anticipated in H2 2026. Company expects to initiate multiple MRT-8102 Phase 2 studies, including in patients with elevated atherosclerotic risk in H2 2026, in patients with gout flares in Q4 2026/Q1 2027, and in patients with moderate to severe hidradenitis suppurativa in H1 2027. VAV1-directed MGD MRT-6160 advancing toward anticipated initiation by Novartis of multiple Phase 2 studies in immune-mediated diseases. Strong balance sheet with cash, cash equivalents, restricted cash, and marketable securities of. $671 million, expected to support operations into 2029. BOSTON, May 07, 2026  -- Monte Rosa Therapeutics, Inc. , a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, today reported business highlights and financial results fo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4539","BK4022","METV","BK4213","GLUE","BK4232","AR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633839926","title":"Monte Rosa CEO Markus Warmuth sells 5,467 shares for $103,443.57","url":"https://stock-news.laohu8.com/highlight/detail?id=2633839926","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633839926?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:05","pubTimestamp":1778011554,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics President and CEO Markus Warmuth sold 5,467 common shares on May 1, 2026.Sale priced at weighted average USD 18.92 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL7pPn3v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Monte Rosa CEO Markus Warmuth sells 5,467 shares for $103,443.57","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633925437","title":"Monte Rosa grants inducement awards: options for 38,925 shares at $18.8 exercise price","url":"https://stock-news.laohu8.com/highlight/detail?id=2633925437","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633925437?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:03","pubTimestamp":1778011404,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics granted inducement equity awards to four newly hired non-executive employees under its 2026 Inducement Plan.Awards include non-qualified stock options covering 38,925 shares, priced at $18.8 per share based on May 1, 2026 close; 25% vests after one year, remainder vests monthly over three years.Grants also include restricted stock units covering 8,550 shares; 25% vests on each of first four anniversaries of grant date.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL8FZ7Ws:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014021.USD","BK4585","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","IE00B64PRP62.GBP","SG9999014013.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","BK4588","LU2210150020.SGD","BK4539","LU0314104364.USD","NDAQ","SG9999014039.USD","BK4139","SG9999014005.SGD","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633259669","title":"Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633259669","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633259669?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:01","pubTimestamp":1778011262,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nTUA3JZDST:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","GLUE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631523277","title":"Monte Rosa Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2631523277","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631523277?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:03","pubTimestamp":1777492998,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics scheduled 2026 annual stockholders meeting for June 11, 2026, to be held online.Shareholders set to vote on election of three Class II directors to serve until 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL6nCqKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","GLUE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629800330","title":"What You Need To Know About The Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Analyst Downgrade Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2629800330","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629800330?lang=en_us&edition=fundamental","pubTime":"2026-04-21 18:20","pubTimestamp":1776766838,"startTime":"0","endTime":"0","summary":"One thing we could say about the analysts on Monte Rosa Therapeutics, Inc. ( NASDAQ:GLUE ) - they aren't optimistic...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/what-you-need-to-know-about-the-monte-rosa-therapeutics-inc","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/what-you-need-to-know-about-the-monte-rosa-therapeutics-inc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GLUE",".IXIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628728972","title":"Monte Rosa Therapeutics to present preclinical data on MRT-55811","url":"https://stock-news.laohu8.com/highlight/detail?id=2628728972","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628728972?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:08","pubTimestamp":1776686902,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics (GLUE) announced the company will present preclinical data highlighting the potential of its highly selective, first-in-cla...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-to-present-preclinical-data-on-mrt-55811-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-to-present-preclinical-data-on-mrt-55811-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLUE","BK4539","MRT","BK4139","BK4230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628742619","title":"Monte Rosa presents CCNE1 degrader data at AACR meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2628742619","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628742619?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:03","pubTimestamp":1776682984,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics will present preclinical data on cyclin E1 -directed molecular glue degrader MRT-55811 at AACR Annual Meeting 2026 on April 21, 2026.Talk is scheduled for 2:30 p.m. to 4:30 p.m. PT in minisymposium “Targeted Protein Degradation and Non-canonical Oncogenic Signaling.”","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL9M0GyG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4539","SG9999014005.SGD","LU0314104364.USD","IE00BKPKM429.USD","SG9999014039.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","SG9999014013.SGD","BK4588","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014021.USD","IE00BN0W2V16.EUR","NDAQ","BK4139","GLUE","IE00B64PRP62.GBP","BK4112","LU2095319765.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.monterosatx.com","stockEarnings":[{"period":"1week","weight":0.0107},{"period":"1month","weight":-0.0962},{"period":"3month","weight":-0.0053},{"period":"6month","weight":0.3277},{"period":"1year","weight":3.7082},{"period":"ytd","weight":0.2041}],"compareEarnings":[{"period":"1week","weight":-0.0073},{"period":"1month","weight":0.0549},{"period":"3month","weight":0.0773},{"period":"6month","weight":0.127},{"period":"1year","weight":0.2743},{"period":"ytd","weight":0.0892}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.040424},{"month":2,"riseRate":0.4,"avgChangeRate":-0.031875},{"month":3,"riseRate":0.4,"avgChangeRate":0.028615},{"month":4,"riseRate":0.4,"avgChangeRate":-0.132561},{"month":5,"riseRate":0.2,"avgChangeRate":-0.010539},{"month":6,"riseRate":0.5,"avgChangeRate":0.041063},{"month":7,"riseRate":0.8,"avgChangeRate":0.071272},{"month":8,"riseRate":0.4,"avgChangeRate":0.098753},{"month":9,"riseRate":0.4,"avgChangeRate":-0.025082},{"month":10,"riseRate":0.8,"avgChangeRate":0.245263},{"month":11,"riseRate":0.4,"avgChangeRate":0.027512},{"month":12,"riseRate":0.4,"avgChangeRate":0.082538}],"exchange":"NASDAQ","name":"Monte Rosa Therapeutics","nameEN":"Monte Rosa Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monte Rosa Therapeutics,GLUE,Monte Rosa Therapeutics股票,Monte Rosa Therapeutics股票老虎,Monte Rosa Therapeutics股票老虎国际,Monte Rosa Therapeutics行情,Monte Rosa Therapeutics股票行情,Monte Rosa Therapeutics股价,Monte Rosa Therapeutics股市,Monte Rosa Therapeutics股票价格,Monte Rosa Therapeutics股票交易,Monte Rosa Therapeutics股票购买,Monte Rosa Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}